However, since the patient met Chompret's criteria (2015, Table 1) with multiple cancers and early-onset breast cancer in the ‘core' tumors, we performed germline TP53 genetic testing (FALCO Ltd., Kyoto, Japan), with her consent (written informed consent was obtained from the patient). Here, TP53 is linked to breast carcinoma.